Journal Home > Volume 6 , Issue 1

Magnetic nanoparticles have been used as drug delivery vehicles against a number of cancer cells. Most of these theranostic formulations have used solid iron oxide nanoparticles (SIONPs) loaded with chemotherapeutics as nano-carrier formulation for both magnetic resonance imaging (MRI) and cancer therapy. In this study, we applied the dopamine-plus-human serum albumin (HSA) method to modify hollow iron oxide nanoparticles (HIONPs) and encapsuated doxorubicin (DOX) within the hollow porous structure of the nano-carrier. The new delivery system can load more drug than solid iron oxide nanoparticles of the same core size using the same coating strategy. The HIONPs–DOX formulation also has a pH-dependent drug release behaviour. Compared with free DOX, the HIONPs–DOX were more effectively uptaken by the multidrug resistant OVCAR8-ADR cells and consequently more potent in killing drug resistant cancer cells. MRI phantom and cell studies also showed that the HIONPs–DOX can decrease the T2 MRI signal intensity and can be used as a MRI contrast agent while acting as a drug delivery vehicle. For the first time, the dual application of chemo drug transport and MR imaging using the HIONPs–DOX formulation was achieved against both DOX-sensitive and DOX-resistant cancer cells.

File
nr-6-1-1_ESM.pdf (338 KB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 01 October 2012
Revised: 31 October 2012
Accepted: 03 November 2012
Published: 30 November 2012
Issue date: January 2013

Copyright

© Tsinghua University Press and Springer-Verlag Berlin Heidelberg 2012

Acknowledgements

Acknowledgements

This research was supported in part by the National Basic Research Program of China (973 Program, Nos. 2013CB733802 and 2010CB934602); the National Science Foundation of China (NSFC, Nos. 81101101, 81201086, 81201129, 81201190, 51273165, 51172005 and 81028009); the Chinese Academy of Sciences Professorship for Senior International Scientists (No. 2011T2J06); and the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH). R. X. is partially supported by the China Scholarship Council.

Return